These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 35183043)

  • 1. Correlation between treatment effects on response rate and progression-free survival and overall survival in trials of targeted therapies in molecularly enriched populations.
    Solomon BJ; Loong HH; Summers Y; Thomas ZM; French P; Lin BK; Sashegyi A; Wolf J; Yang JC; Drilon A
    ESMO Open; 2022 Apr; 7(2):100398. PubMed ID: 35183043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis.
    Cremolini C; Antoniotti C; Pietrantonio F; Berenato R; Tampellini M; Baratelli C; Salvatore L; Marmorino F; Borelli B; Nichetti F; Bironzo P; Sonetto C; Bartolomeo MD; Braud F; Loupakis F; Falcone A; Di Maio M
    Cancer Res Treat; 2017 Jul; 49(3):834-845. PubMed ID: 27857020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer: A Systematic Review and Meta-analysis.
    Paoletti X; Lewsley LA; Daniele G; Cook A; Yanaihara N; Tinker A; Kristensen G; Ottevanger PB; Aravantinos G; Miller A; Boere IA; Fruscio R; Reyners AKL; Pujade-Lauraine E; Harkin A; Pignata S; Kagimura T; Welch S; Paul J; Karamouza E; Glasspool RM;
    JAMA Netw Open; 2020 Jan; 3(1):e1918939. PubMed ID: 31922558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Objective response rate and progression-free survival as surrogates for overall survival treatment effect: A meta-analysis across diverse tumour groups and contemporary therapies.
    Shahnam A; Hitchen N; Nindra U; Manoharan S; Desai J; Tran B; Solomon B; Luen SJ; Hui R; Hopkins AM; Sorich MJ
    Eur J Cancer; 2024 Feb; 198():113503. PubMed ID: 38134560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between biomarkers and treatment outcomes in diverse cancers: a systematic review and meta-analysis of phase I and II immunotherapy clinical trials.
    Fountzilas E; Vo HH; Mueller P; Kurzrock R; Tsimberidou AM
    Eur J Cancer; 2023 Aug; 189():112927. PubMed ID: 37364526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection bias in open-label trials of anticancer drugs: a meta-epidemiological study.
    Funada S; Luo Y; Kataoka Y; Yoshioka T; Fujita Y; Yoshida S; Katsura M; Tada M; Nishioka N; Nakamura Y; Ueno K; Uozumi R; Furukawa TA
    BMJ Evid Based Med; 2023 Nov; 28(6):372-382. PubMed ID: 37586872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surrogate endpoints in phase III randomized trials of advanced gastroesophageal cancer: A systematic review and meta-analysis.
    Veas Rodríguez J; Prieto A; Vilaprinyo E; Bonet M; Diez M; Salud A; Montal R
    Crit Rev Oncol Hematol; 2024 Sep; 201():104416. PubMed ID: 38871262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response Rate as a Regulatory End Point in Single-Arm Studies of Advanced Solid Tumors.
    Oxnard GR; Wilcox KH; Gonen M; Polotsky M; Hirsch BR; Schwartz LH
    JAMA Oncol; 2016 Jun; 2(6):772-9. PubMed ID: 26914340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validity and Efficiency of Progression-Free Survival-2 as a Surrogate End Point for Overall Survival in Advanced Cancer Randomized Trials.
    Woodford R; Zhou D; Kok PS; Lord SJ; Friedlander M; Marschner I; Simes RJ; Lee CK
    JCO Precis Oncol; 2024 Jan; 8():e2300296. PubMed ID: 38207226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk and benefit for umbrella trials in oncology: a systematic review and meta-analysis.
    Strzebonska K; Blukacz M; Wasylewski MT; Polak M; Gyawali B; Waligora M
    BMC Med; 2022 Jul; 20(1):219. PubMed ID: 35799149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale and design of the CRAFT (Continuous ReAssessment with Flexible ExTension in Rare Malignancies) multicenter phase II trial.
    Heilig CE; Horak P; Kreutzfeldt S; Teleanu V; Mock A; Renner M; Bhatti IA; Hutter B; Hüllein J; Fröhlich M; Uhrig S; Süße H; Heiligenthal L; Ochsenreither S; Illert AL; Vogel A; Desuki A; Heinemann V; Heidegger S; Bitzer M; Scheytt M; Brors B; Hübschmann D; Baretton G; Stenzinger A; Steindorf K; Benner A; Jäger D; Heining C; Glimm H; Fröhling S; Schlenk RF
    ESMO Open; 2021 Dec; 6(6):100310. PubMed ID: 34808524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-Analysis of 49 Roche Oncology Trials Comparing Blinded Independent Central Review (BICR) and Local Evaluation to Assess the Value of BICR.
    Lian Q; Fredrickson J; Boudier K; Rothkegel C; Hilton M; Hillebrecht A; McDonald A; Xu N
    Oncologist; 2024 Aug; 29(8):e1073-e1081. PubMed ID: 36905580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progression-free survival is a weakly predictive surrogate end-point for overall survival in follicular lymphoma: A systematic review and meta-analysis.
    Milrod CJ; Kim KW; Raker C; Ollila TA; Olszewski AJ; Pelcovits A
    Br J Haematol; 2024 Jun; 204(6):2237-2241. PubMed ID: 38571449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology.
    Hess LM; Brnabic A; Mason O; Lee P; Barker S
    J Cancer; 2019; 10(16):3717-3727. PubMed ID: 31333789
    [No Abstract]   [Full Text] [Related]  

  • 15. Recent Status of Phase I Clinical Trials for Brain Tumors: A Regulatory Science Study of Exploratory Efficacy Endpoints.
    Watanabe S; Nonaka T; Maeda M; Yamada M; Sugii N; Hashimoto K; Takano S; Koyanagi T; Arakawa Y; Ishikawa E
    Ther Innov Regul Sci; 2024 Jul; 58(4):655-662. PubMed ID: 38530629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RECISTv1.1 progression in oncology: Shades of gray.
    Topp B; Snyder A; Wolchok J
    Cancer Cell; 2023 Jun; 41(6):1003-1005. PubMed ID: 37172579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Joint modeling of tumor dynamics and progression-free survival in advanced breast cancer: Leveraging data from amcenestrant early phase I-II trials.
    Cerou M; Thai HT; Deyme L; Fliscounakis-Huynh S; Comets E; Cohen P; Cartot-Cotton S; Veyrat-Follet C
    CPT Pharmacometrics Syst Pharmacol; 2024 Jun; 13(6):941-953. PubMed ID: 38558299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross-sectional analysis characterizing the use of rank preserving structural failure time in oncology studies: changes to hazard ratio and frequency of inappropriate use.
    Prasad V; Kim MS; Haslam A
    Trials; 2023 Jun; 24(1):373. PubMed ID: 37270500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel Bayesian generative approach for estimating tumor dynamics from published studies.
    Pourzanjani A; Modi S; Connarn J; Zhang X; Upreti V; Lin CW; Mehta K
    CPT Pharmacometrics Syst Pharmacol; 2024 Aug; 13(8):1341-1353. PubMed ID: 38778515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proportional Hazards Violations in Phase 3 Cancer Clinical Trials: A Potential Source of Trial Misinterpretation.
    Lin TA; McCaw ZR; Koong A; Lin C; Abi Jaoude J; Patel R; Kouzy R; El Alam MB; Sherry AD; Noticewala SS; Fuller CD; Thomas CR; Sun R; Lee JJ; Lin R; Yuan Y; Shyr Y; Meirson T; Ludmir EB
    Clin Cancer Res; 2024 Aug; ():. PubMed ID: 39133081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.